The Future of Targeted Therapy in MDS

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: November 30, 2018
Expiration Date: November 30, 2019

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In order to tailor a treatment approach to each individual patient, it is vital to understand how to identify molecular markers to select targeted therapies. Practitioners may be challenged with making these therapeutic decisions without sufficient knowledge of efficacy and safety data on available targeted therapies. The development of potential future targeted agents increases the burden on healthcare providers. In this activity, Dr. McCurdy reviews current and emerging targeted therapies and their role in the treatment of MDS.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify molecular markers that may be used to identify treatment in patients with MDS
  • Assess the future of targeted therapies for the treatment of MDS
  • Evaluate the efficacy and safety of currently available molecularly-targeted therapies in MDS
  • Review emerging targeted therapies and their possible role in the treatment of MDS


The Future of Targeted Therapy in MDS – Shannon R. McCurdy, MD

Instructions for Participation and Credit

This activity is eligible for credit through November 30, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Shannon R. McCurdy, MD 
Assistant Professor
Department of Hematology Oncology
Hospital of The University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Shannon McCurdy received her medical degree from Georgetown University School of Medicine. She was an intern and resident in internal medicine at the Hospital of the University of Pennsylvania and completed her clinical and research fellowships in oncology at The Johns Hopkins Hospital. She is currently an Assistant Professor of Medicine at the Hospital of the University of Pennsylvania School of Medicine, and was previously an Assistant Professor at Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins Hospital.

Dr. McCurdy holds American Board of Internal Medicine certification in internal medicine and medical oncology. She is a member of the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the American Society for Blood and Marrow Transplantation. She has served as an abstract reviewer and/or moderator at annual meetings including American Society of Hematology and the Tandem Meetings of ASBMT and CIBMTR. Dr. McCurdy has published her original research in Blood, Journal of Clinical Oncology, Biology of Bone Marrow Transplantation, Haematologica, Leukemia, and Blood Advances. Dr. McCurdy is a reviewer for the American Journal of Hematology, Biology of Bone Marrow Transplantation, Clinical Chemistry, and Blood, among others. Her current research is on optimizing treatment strategies for older patients with hematologic malignancies with a special focus on allogeneic blood or marrow transplantation.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-048-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Shannon McCurdy has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Onconova Therapeutics Inc.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.